株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

おたふく風邪 : パイプライン分析

Mumps - Pipeline Review, H2 2017

発行 Global Markets Direct 商品コード 271822
出版日 ページ情報 英文 32 Pages
即納可能
価格
本日の銀行送金レート: 1USD=113.76円で換算しております。
Back to Top
おたふく風邪 : パイプライン分析 Mumps - Pipeline Review, H2 2017
出版日: 2017年07月18日 ページ情報: 英文 32 Pages
概要

おたふく風邪とはウイルス性の接触感染症で、唾液腺に痛みを伴う腫脹が生じます。病原ウイルスは、個人間の飛沫感染(鼻水など)や、ウイルス入り唾液のかかった物への直接接触などにより広がっていきます。主な症状として、発熱や顔面の痛み、頭痛、喉の痛み、こめかみや顎の腫れ、耳下腺の腫脹などが挙げられます。主な治療法としては、(症状緩和のための)鎮痛剤などがあります。

当レポートでは、世界各国でのおたふく風邪(流行性耳下腺炎)治療用のパイプライン製品の開発状況について分析し、パイプライン製品の開発・上市の最新動向や、治験の各段階にある製品の一覧、主要企業のプロファイル、主な薬剤の概要、最新の業界動向などを調査して、その結果を概略以下の構成でお届けします。

目次

イントロダクション

  • 分析範囲

おたふく風邪の概要

治療薬の開発

  • おたふく風邪向けパイプライン製品:概要
  • おたふく風邪向けパイプライン製品:比較分析

各企業で開発中のおたふく風邪治療薬

大学/研究機関で研究中のおたふく風邪治療薬

パイプライン製品の概略

  • 後期段階の製品
  • 治験段階の製品
  • 初期段階の製品

おたふく風邪治療薬:開発中の製品の一覧(企業別)

おたふく風邪治療薬:研究中の製品の一覧(大学/研究機関別)

おたふく風邪治療薬の開発に従事している企業

  • Beijing Minhai Biotechnology Co., Ltd
  • Beijing Tiantan Biological Products Co., Ltd.
  • China National Pharmaceutical Group Corporation
  • GlaxoSmithKline Plc
  • Organic Vaccines
  • Prometheon Pharma, LLC
  • Sinovac Biotech Ltd.
  • Zydus Cadila Healthcare Limited

おたふく風邪:治療薬の評価

  • 単剤治療薬の場合
  • 併用治療薬の場合
  • 投与方法別
  • 分子の種類別

薬剤のプロファイル

  • 麻疹・おたふく風邪・風疹(MMR)向け細胞療法
    • 製品概要
    • 機能メカニズム
    • 研究開発(R&D)の進展状況
  • MMR+水痘ワクチン
  • MMR生ワクチン(新三種混合ワクチン)
  • 麻疹strain schwarz ・おたふく風邪strain RIT 4385・風疹strain wistar RA 27/3向けワクチン
  • おたふく風邪ワクチン

おたふく風邪治療薬:パイプライン製品の最新動向

おたふく風邪治療薬:開発が休止状態の製品

おたふく風邪関連製品の開発のマイルストーン

  • 注目すべき最新動向・プレスリリース

付録

図表一覧

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC9558IDB

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Mumps - Pipeline Review, H2 2017, provides an overview of the Mumps (Infectious Disease) pipeline landscape.

Mumps is a contagious disease that leads to painful swelling of the salivary glands. The mumps are caused by a virus. The virus is spread from person-to-person by respiratory droplets (for example, when you sneeze) or by direct contact with items that have been contaminated with infected saliva. Symptoms include fever, face pain, headache, sore throat, swelling of the temples or jaw and swelling of the parotid glands. Treatment includes pain relievers (to get relief for symptoms).

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Mumps - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Mumps (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Mumps (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Mumps and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Unknown stages are 2, 1, 1, 1, 1 and 1 respectively. Similarly, the Universities portfolio in Phase II and Preclinical stages comprises 1 and 1 molecules, respectively.

Mumps (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Mumps (Infectious Disease).
  • The pipeline guide reviews pipeline therapeutics for Mumps (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Mumps (Infectious Disease) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Mumps (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Mumps (Infectious Disease)

Reasons to buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Mumps (Infectious Disease).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Mumps (Infectious Disease) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Mumps - Overview
    • Mumps - Therapeutics Development
    • Pipeline Overview
    • Pipeline by Companies
    • Pipeline by Universities/Institutes
    • Products under Development by Companies
    • Products under Development by Universities/Institutes
  • Mumps - Therapeutics Assessment
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Mumps - Companies Involved in Therapeutics Development
    • Beijing Minhai Biotechnology Co Ltd
    • Daiichi Sankyo Company Ltd
    • GlaxoSmithKline Plc
    • Sinovac Biotech Ltd
    • Zydus Cadila Healthcare Ltd
  • Mumps - Drug Profiles
    • (measles + mumps + rubella + varicella) vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • (measles + mumps + rubella) vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • (measles + mumps + rubella) vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • (measles + mumps + rubella) vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • (measles [strain Schwarz] + mumps [strain RIT 4385] + rubella [strain Wistar RA 27/3]) vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • mumps vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • mumps vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • mumps vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • VN-0102 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Mumps - Dormant Projects
  • Mumps - Product Development Milestones
    • Featured News & Press Releases
      • Jun 13, 2012: UGA researcher developing new vaccine to fight resurging mumps virus
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development for Mumps, H2 2017
  • Number of Products under Development by Companies, H2 2017
  • Number of Products under Development by Universities/Institutes, H2 2017
  • Products under Development by Companies, H2 2017
  • Products under Development by Universities/Institutes, H2 2017
  • Number of Products by Stage and Route of Administration, H2 2017
  • Number of Products by Stage and Molecule Type, H2 2017
  • Mumps - Pipeline by Beijing Minhai Biotechnology Co Ltd, H2 2017
  • Mumps - Pipeline by Daiichi Sankyo Company Ltd, H2 2017
  • Mumps - Pipeline by GlaxoSmithKline Plc, H2 2017
  • Mumps - Pipeline by Sinovac Biotech Ltd, H2 2017
  • Mumps - Pipeline by Zydus Cadila Healthcare Ltd, H2 2017
  • Mumps - Dormant Projects, H2 2017

List of Figures

  • Number of Products under Development for Mumps, H2 2017
  • Number of Products under Development by Companies, H2 2017
  • Number of Products under Development by Universities/Institutes, H2 2017
  • Number of Products by Routes of Administration, H2 2017
  • Number of Products by Stage and Routes of Administration, H2 2017
  • Number of Products by Molecule Types, H2 2017
  • Number of Products by Stage and Molecule Types, H2 2017
Back to Top